
Sales of weight loss drug Wegovy more than doubled in the final three months of 2024 but its manufacturer has predicted growth will slow this year.
Novo Nordisk's rise to become one of Europe's most valuable companies has been fuelled by the exploding demand for its obesity treatments, including Wegovy.